Pablo Pavia-Garcia
Pozuelo De Alarcon, MD, Spain
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 372 publications
Gene Silencer Therapy in Transthyretin Amyloid Cardiomyopathy: A Meta-Analysis of Outcomes Trials.
Journal: JAMA
Published: August 30, 2026
Aficamten for Symptomatic Nonobstructive Hypertrophic Cardiomyopathy.
Journal: The New England journal of medicine
Published: August 28, 2026
Eplontersen for Transthyretin Amyloid Cardiomyopathy.
Journal: The New England journal of medicine
Published: August 28, 2026
Effect of acoramidis on risk of death and heart problem-related hospitalizations in people with transthyretin amyloid cardiomyopathy: a plain language summary.
Journal: Future cardiology
Published: August 05, 2026
Cardiomyocyte-Specific Inhibition of p53 Signaling as a Therapeutic Strategy for Arrhythmogenic Right Ventricular Cardiomyopathy Type 5.
Journal: Circulation research
Published: August 04, 2026
Left Ventricular Hypertrabeculation and Prognosis in Dilated Cardiomyopathy.
Journal: Circulation
Published: August 03, 2026
Effect of Acoramidis on Heart Failure-Related Health Status: A Secondary Analysis of the ATTRibute-CM Randomized Clinical Trial.
Journal: JAMA cardiology
Published: July 29, 2026
Guidelines for the management of hereditary ATTR amyloidosis 2026.
Journal: Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis
Published: July 09, 2026
Influence of Disease-Modifying Therapy on the Efficacy of Vutrisiran in Transthyretin Cardiac Amyloidosis.
Journal: Journal of the American College of Cardiology
Published: June 22, 2026
Effect of Vutrisiran According to Baseline Tafamidis Use in Transthyretin Amyloidosis With Cardiomyopathy: Insights From HELIOS-B.
Journal: Journal of the American College of Cardiology
Published: June 22, 2026
Last Updated: 09/26/2026